<DOC>
	<DOCNO>NCT02103101</DOCNO>
	<brief_summary>Vitamin K antagonists hamper several disadvantage , need frequent monitoring . In context , new oral anticoagulant ( NOACs ) develop available market . These NOACs , like anticoagulant drug , continue associate increased risk bleeding . In addition , lack antidote absence valid data regard biological monitoring pose problem case overdose emergency surgery require . Studies investigate pharmacokinetic property rivaroxaban dabigatran , two NOACs approve market , show high variability individual , coefficient variation 60 % pharmacokinetic parameter patient treat orthopaedic surgery . The relation plasma concentration NOAC bleed risk clearly establish clinical trial . Dabigtran , rivaroxaban apixaban know substrates P-glycoprotein ( Pgp ) . Pgp activity affect pharmacological inducing inhibit agent . This lead significant change pharmacokinetics NOACs , decrease increase ( respectively ) level intestinal absorption , lead respectively reduce increase plasma concentration drug . Furthermore , exist genetic mutation Pgp , present particular low level activity non-mutated protein . We hypothesize polymorphism ( mutation ) ABCB1 gene code Pgp could influence plasma concentration dabigatran , rivaroxaban apixaban , consequently , impact concentration NOACs corollary , bleed thromboembolic risk patient treat molecule . The main objective study study relation polymorphism ABCB1 gene code Pgp plasma concentration NOACs patient treat hemorrhagic thromboembolic complication occur NOAC therapy . Secondary objective evaluate distribution ABCB1 polymorphism among various hemorrhagic risk factor , compare frequency polymorphism patient study population v general population .</brief_summary>
	<brief_title>Influence ABCB1 Polymorphisms Plasma Concentrations New Oral Anticoagulants Case Serious Adverse Events</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients age &gt; 18 &lt; 80 year age Patients admit University Hospital Besancon serious adverse event ( major bleed complication thromboembolic event ) occur treatment one three commercially available new oral anticoagulant agent ( rivaroxaban , apixaban dabigatran ) . Patients must social security coverage . Patients must provide write informed consent . Hemorrhagic complication cause related drug therapy Hemorrhagic complication occur patient treated oral anticoagulant time event Thromboembolic complication occur patient treated oral anticoagulant time event Legal incapacity , patient judicial protection Patients social security coverage Patients unlikely compliant anticipate investigator noncompliant study requirement Patients washout period participation previous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>polymorphism</keyword>
	<keyword>ABCB1</keyword>
	<keyword>P-glycoprotein</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>dabigatran</keyword>
	<keyword>apixaban</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>hemorrhagic complication</keyword>
	<keyword>thrombo-embolism</keyword>
	<keyword>serious adverse event</keyword>
</DOC>